Education
About Us
Working with TipRanks
Follow Us
Molecular Partners (MOLN)
NASDAQ:MOLN
MOLN Stock Chart & Stats
$4.32
-$0.03(-0.55%)
At close: 4:00 PM EST
$4.32
-$0.03(-0.55%)
Day’s Range― - ―
52-Week Range$3.36 - $5.91
Previous CloseN/A
Volume8.30K
Average Volume (3M)2.31K
Market Cap
$159.77M
Enterprise Value$1.32M
Total Cash (Recent Filing)$104.52M
Total Debt (Recent Filing)$1.53M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Mar 12, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding40,374,640
10 Day Avg. Volume2,377
30 Day Avg. Volume2,311
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.04
Price to Sales (P/S)29.53
P/FCF Ratio-2.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.03
Enterprise Value/Ebitda-0.02
Forecast
1Y Price Target
$10.00Price Target Upside131.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressMOLN reiterated plans for initiating a company-sponsored Phase 1 by the end of 2025 with longer-term plans for registration opportunities in SCLC and other neuroendocrine carcinomas.
Drug EfficacyMP0712 has achieved ~60% injected dose on the tumor due to radio-DARPin half-life extension via albumin binding and rapid DLL3 internalization & recycling.
Financial StabilityAs of 9/30/2025, MOLN had CHF 105M cash and equivalents, which will support its runway until 2028.
Bears Say
Treatment ChallengesThe benefit of obinutuzumab pretreatment remained limited, indicating challenges in enhancing treatment efficacy.
Treatment EffectivenessThe presence of anti-drug antibodies coincided with reduced serum MP0533 exposure levels and the loss of T cell activation in 53% of patients, limiting the treatment's effectiveness.
Tumor TargetingIn spite of DLL3's 'very low' cell surface density, MP0712 has achieved ~60% injected dose on the tumor.
Molecular Partners News
MOLN FAQ
What was Molecular Partners’s price range in the past 12 months?
Molecular Partners lowest stock price was $3.36 and its highest was $5.91 in the past 12 months.
What is Molecular Partners’s market cap?
Molecular Partners’s market cap is $159.77M.
When is Molecular Partners’s upcoming earnings report date?
Molecular Partners’s upcoming earnings report date is Mar 12, 2026 which is in 88 days.
How were Molecular Partners’s earnings last quarter?
Molecular Partners released its earnings results on Aug 25, 2025. The company reported -$0.687 earnings per share for the quarter, missing the consensus estimate of -$0.474 by -$0.213.
Is Molecular Partners overvalued?
According to Wall Street analysts Molecular Partners’s price is currently Undervalued.
Does Molecular Partners pay dividends?
Molecular Partners does not currently pay dividends.
What is Molecular Partners’s EPS estimate?
Molecular Partners’s EPS estimate is -0.39.
How many shares outstanding does Molecular Partners have?
Molecular Partners has 40,374,640 shares outstanding.
What happened to Molecular Partners’s price movement after its last earnings report?
Molecular Partners reported an EPS of -$0.687 in its last earnings report, missing expectations of -$0.474. Following the earnings report the stock price went down -7.82%.
Which hedge fund is a major shareholder of Molecular Partners?
Currently, no hedge funds are holding shares in MOLN
Company Description
Molecular Partners
Molecular Partners AG is a clinical-stage biotechnology company based in Switzerland, focused on the development of innovative therapies using its proprietary DARPins (designed ankyrin repeat proteins) technology platform. The company primarily operates in the biopharmaceutical sector, concentrating on the discovery and development of targeted treatments for various diseases, including cancer and infectious diseases. Its core products include a range of DARPin-based therapeutics, which are engineered proteins designed to bind specifically to disease targets, enhancing the therapeutic potential and specificity of treatments.
MOLN Stock 12 Month Forecast
Average Price Target
$10.00
▲(131.48% Upside)
Technical Analysis
Compugen
―
Oncolytics Biotech
―
Oncolytics Biotech
―
Nkarta
―
C4 Therapeutics
―
Shattuck Labs
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
8.86% Other Institutional Investors
91.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---